653.0000 -12.10 (-1.82%)
NSE Apr 17, 2025 15:31 PM
Volume: 289.2K
 

653.00
-1.82%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma Science Ltd. is trading above its 50 day SMA of 650.0
More from Strides Pharma Science Ltd.
Recommended